These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35624408)

  • 1. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
    Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A
    Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
    Morice A; Smith JA; McGarvey L; Birring SS; Parker SM; Turner A; Hummel T; Gashaw I; Fels L; Klein S; Francke K; Friedrich C
    Eur Respir J; 2021 Nov; 58(5):. PubMed ID: 33986030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.
    Klein S; Gashaw I; Baumann S; Chang X; Hummel T; Thuß U; Friedrich C
    Br J Clin Pharmacol; 2022 Oct; 88(10):4552-4564. PubMed ID: 35437837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants.
    Li X; Haranaka M; Li H; Liu P; Chen H; Klein S; Reif S; Francke K; Friedrich C; Okumura K
    Clin Pharmacokinet; 2024 Jun; 63(6):901-915. PubMed ID: 38907175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men.
    Friedrich C; Singh D; Francke K; Klein S; Hetzel T; Zolk O; Gashaw I; Scheerans C; Morice A
    Br J Clin Pharmacol; 2024 Aug; 90(8):2004-2018. PubMed ID: 38775025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study.
    Dicpinigaitis PV; Morice AH; Smith JA; Sher MR; Vaezi M; Guilleminault L; Niimi A; Gude K; Krahn U; Saarinen R; Pires PV; Wosnitza M; McGarvey L;
    Lung; 2023 Jun; 201(3):255-266. PubMed ID: 37261531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
    Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
    Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial.
    Friedrich C; Francke K; Birring SS; van den Berg JWK; Marsden PA; McGarvey L; Turner AM; Wielders P; Gashaw I; Klein S; Morice AH
    Respir Res; 2023 Apr; 24(1):109. PubMed ID: 37041539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
    Garceau D; Chauret N
    Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: A systematic review and meta-analysis of 11 randomized controlled trials.
    Ramadan A; El-Samahy M; Elrosasy A; Al-Tawil M; Abdelaziz A; Soliman MA; Abouzid M
    Pulm Pharmacol Ther; 2023 Dec; 83():102252. PubMed ID: 37678663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
    Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant.
    Francke K; Chattopadhyay N; Klein S; Rottmann A; Krickau D; van de Wetering J; Friedrich C
    Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):75-87. PubMed ID: 36469250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.
    Nussbaum JC; Hussain A; Butera P; Ford AP; Kitt MM; O'Neill EA; Smith S; Vargas G; O'Reilly T; Wynne C; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2024 Aug; 64(8):1023-1029. PubMed ID: 38651193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of gefapixant, a P2X
    McGarvey LP; Birring SS; Morice AH; Dicpinigaitis PV; Pavord ID; Schelfhout J; Nguyen AM; Li Q; Tzontcheva A; Iskold B; Green SA; Rosa C; Muccino DR; Smith JA;
    Lancet; 2022 Mar; 399(10328):909-923. PubMed ID: 35248186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers.
    Davenport AJ; Neagoe I; Bräuer N; Koch M; Rotgeri A; Nagel J; Laux-Biehlmann A; Machet F; Coelho AM; Boyce S; Carty N; Gemkow MJ; Hess SD; Zollner TM; Fischer OM
    Sci Rep; 2021 Oct; 11(1):19877. PubMed ID: 34615939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
    Abdulqawi R; Dockry R; Holt K; Layton G; McCarthy BG; Ford AP; Smith JA
    Lancet; 2015 Mar; 385(9974):1198-205. PubMed ID: 25467586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough: Dose-Response Model-Based Network Meta-Analysis.
    Yamamoto S; Horita N; Hara J; Sasamoto M; Kanemitsu Y; Hara Y; Obase Y; Kaneko T; Niimi A; Mukae H
    Chest; 2024 Jun; ():. PubMed ID: 38857780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study.
    Parke S; Gude K; Roth K; Messina F
    BMC Womens Health; 2024 Jun; 24(1):353. PubMed ID: 38890641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.